Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.39 |
| ▸ | PDE4A | P27815 | 9/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276177 | 0.85 | POLB (0.44) | ERN1PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL275132 | 0.82 | PTGDR2 (0.44) | SYKERN1PDE4DPDE4BPDE4A | |
| SCHEMBL275678 | 0.82 | SYK (0.45) | SYKPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL275979 | 0.82 | CHEK1 (0.42) | SYKERN1PDE4DPDE4BPDE4A | |
| SCHEMBL8115816 | 0.78 | KAT2B (0.52) | SYKPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1613268 | 0.77 | SYK (0.44) | SYKPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17210752 | 0.76 | PDE4D (0.55) | SYKPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1611708 | 0.75 | BCL6 (0.45) | SYKPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17352923 | 0.74 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL31006004 | 0.74 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217051-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217051-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217051-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2398801-A1 | 3, 3' -SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| EP-2229396-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2229396-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2010094622-A1 | 3, 3' -SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210674-A1 | Spiroindolinone Derivatives | HOFFMANN-LA ROCHE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210674-A1 | Spiroindolinone Derivatives | HOFFMANN-LA ROCHE INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210674-A1 | Spiroindolinone Derivatives | HOFFMANN-LA ROCHE INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | SYK 2511/4885ERN1 2608/4885PDE4D 2759/4885 |
| US-20100210674-A1 | Spiroindolinone Derivatives | RCC2, PKD1, SIK2 | SYK 1901/4885ERN1 1142/4885PDE4D 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.